- Trial Phase
- Approved
- Time to Market
- Already launched/marketable — the drug is listed on Greek pharmaceutical registries and Cosmos signed a commercial distribution deal (July 2026) for Greek market rollout.
- Why 4/10
- DIABIT-IS X is already approved as a generic sitagliptin product — no pending PDUFA, pivotal readout, or binary regulatory catalyst. The next milestone is commercial ramp following the July 13, 2026 Libytec distribution partnership in Greece, a revenue-growth event rather than a binary catalyst. With a ~$15-20M market cap and a diversified business (generics, nutraceuticals, contract manufacturing), this one drug is a moderate contributor, not a make-or-break asset, capping impactScore at 4.
Watch Cosmos Health's quarterly filings for actual revenue contribution from DIABIT-IS X sales in Greece. The broader story is the generic portfolio rollout and Cana Labs contract manufacturing ramp — DIABIT-IS X alone is not a binary event. COSM has high short interest (~59.7% short ratio), so positive commercial news could drive short squeezes, but the stock is also down ~67% over 6 months and faces Nasdaq filing delinquency risks.
Price Chart
Executive Summary
DIABIT-IS X is a generic version of sitagliptin (Merck's Januvia), a well-established DPP-4 inhibitor for type 2 diabetes. Cosmos Health (NASDAQ: COSM) acquired the European license and rights for ~$3.5M as part of a 10-drug generic portfolio in December 2023, positioning itself as a first mover after Januvia's European patent expiration. On July 13, 2026, Cosmos signed a five-year distribution partnership with Libytec Pharmaceutical to commercialize the drug in Greece, with the drug accessible through the national health insurance system. As a generic of an off-patent blockbuster (Januvia + Janumet generated $4.5B in 2022 sales), DIABIT-IS X has a clear market path but faces intense generic competition and pricing erosion. Cosmos Health is a small-cap ($15-20M market cap) diversified healthcare group with multiple revenue streams — this one drug is a modest growth contributor, not a needle-mover on its own.
How It Works
DIABIT-IS X contains sitagliptin, a DPP-4 inhibitor. It works by blocking an enzyme that breaks down incretin hormones, which help the pancreas produce more insulin after meals. More insulin means lower blood sugar. Crucially, it only boosts insulin when blood glucose is high, reducing the risk of dangerously low blood sugar (hypoglycemia). It is a once-daily pill for type 2 diabetes.
Trial Status
No clinical trials required — this is a generic version of sitagliptin (Merck's Januvia), which has been approved globally since 2006. The European patent for Januvia expired in late 2021/June 2024, opening the door for generics. DIABIT-IS X is already listed on Greek drug registries (galinos.gr). Cosmos Health acquired the license in December 2023 and signed a five-year commercialization deal with Libytec Pharmaceutical in July 2026.
The Two-Sided Case
Upcoming Catalysts
- Q2 2026 earnings report (preliminary revenue ~$19.4M per Investing.com) — potential color on DIABIT-IS X initial sales in Greece.
- Expansion of DIABIT-IS X into additional European markets beyond Greece (no announced timeline).
- Further Nasdaq compliance updates regarding delinquent SEC filings.
- Share buyback program execution under the existing $5M authorization.
- Contract manufacturing wins for Cana Laboratories facility utilization.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Cosmos Health Inc. Press Release COSM ·Originating report